IXI
VERY GOODIXICO Delivers Double-Digit Revenue Growth in FY25
The healthcare technology company reported double-digit revenue growth and improved profitability in its latest trading update, signaling strong execution of its strategic plan.
IXICO
11.25GBX
0.00%
Market Cap
10.43M
Volume
3.5k
5% of avg
P/E Ratio
-5.36
EPS (TTM)
-2.1
Beta
0.54
Day Range
10.80p - 11.15p
52 Week Range
7.35p11.25p15.00p
11.25p
Upcoming Events
IXI
GOODIXICO Secures £1.2 Million in New Contracts and Extensions
The healthcare technology company has secured a new contract and contract extension worth a total of £1.2 million, demonstrating its expertise in neuroscience imaging and biomarker analytics.
IXI
NEUTRALIXICO Announces Capital Markets Day
The healthcare technology company is hosting a Capital Markets Day for analysts and investors to discuss its growth strategy and technology platform.
IXI
GOODIXICO Secures £1.3 Million in New Neuroscience Imaging Contracts
The healthcare technology company has secured two new contracts worth a combined £1.3 million to provide neuroimaging services for clinical trials in Alzheimer's Disease and Friedreich's Ataxia.
IXI
GOODIXICO Deepens Partnership with Global Alzheimer's Platform Foundation
The healthcare technology company has secured a strategic partnership with a leading Alzheimer's research organization, gaining access to valuable study data to advance its biomarker analytics capabilities.
IXI
GOODIXICO Anticipates Revenues Ahead of Expectations for 2025
The healthcare technology company reports revenues are anticipated to exceed expectations for the year, driven by positive sales momentum and strategic execution.
IXI
NEUTRALIXICO Grants Share Options to Executives
The medical imaging analytics company IXICO has granted share options to its Chief Technology Officer, Chief Business Officer and VP Global Business Development.
IXI
VERY GOODIXICO Assists in FDA Clearance of New Alzheimer's Diagnostic Biomarker
The healthcare technology company has assisted in the FDA clearance of a new blood-based test that will help advance diagnosis and drug development in Alzheimer's disease.
IXI
NEUTRALIXICO Announces Holding Change
The healthcare data analytics company has announced a change in shareholding, with no further details provided.
IXI
NEUTRALIXICO Reports 26% Revenue Growth in Half-Year Results
The neuroscience imaging and biomarker analytics firm reported a 26% increase in revenue and improved gross margins, while still operating at a loss. New contracts and diversification efforts show promise.